Magnesium reversal of digoxin-facilitated ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome

• Published in: The American journal of medicine Vol. 97; no. 1; pp. 25 - 28
• Main Authors: Merrill, James J., DeWeese, Gary, Wharton, J.Marcus
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.07.1994; Elsevier; Elsevier Sequoia S.A
• Subjects: Aged; Antiarythmic agents; Atrial Fibrillation - chemically induced; Atrial Fibrillation - drug therapy; Atrial Fibrillation - physiopathology; Biological and medical sciences; Cardiac arrhythmia; Cardiovascular system; Digoxin - adverse effects; Electrocardiography - drug effects; Female; Heart Rate - drug effects; Heart Ventricles - drug effects; Humans; Magnesium Sulfate - therapeutic use; Male; Medical disorders; Medical research; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Wolff-Parkinson-White Syndrome - drug therapy; Wolff-Parkinson-White Syndrome - physiopathology; Human; Preexcitation ventricular syndrome; Intravenous administration; Arrhythmia; Toxicity; Atrial fibrillation; Cardiovascular disease; Wolff Parkinson White syndrome; Conduction disorder; Excitability disorder; Case study; Heart rate; Chemotherapy; Treatment; Heart disease; Cations; Glycoside; Magnesium; Antiarrhythmia agent
• ISSN: 0002-9343; 1555-7162
• DOI: 10.1016/0002-9343(94)90044-2

In patients with Wolff-Parkinson-White syndrome and atrial fibrillation, digoxin may increase the ventricular rate by facilitating conduction over the accessory pathway either directly by enhancing accessory pathway conduction and/or indirectly as a consequence of its effect on atrioventricular nodal conduction. Two cases are presented in which the intravenous administration of magnesium sulfate reversed digoxin facilitation of the ventricular rate to atrial fibrillation in the Wolff-Parkinson-White syndrome.